{"entity":{"id":"nct05737706","kind":"trial","name":"Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","aka":["MRTX1133 phase 1/2"],"tldr":"A phase 1 trial of MRTX1133 in Non-small-cell lung cancer and Rectal cancer, run by Mirati Therapeutics Inc., recorded as terminated on the registry.","summary":"Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation is a phase 1 interventional study registered as NCT05737706 by Mirati Therapeutics Inc., with 63 participants recorded, started 2023-03-06 and due to reach its primary completion in 2025-03-10. Interventions recorded: MRTX1133. Conditions recorded: Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma.\n\nLinked to the drug MRTX1133 because the registry names it among its interventions and Non-small-cell lung cancer and Rectal cancer among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05737706","url":"https://clinicaltrials.gov/study/NCT05737706"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","rectal-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["mrtx1133"],"companies":["bms"],"institutions":[],"pathways":[],"terms":["pancreatic-failed-programmes","kras-mutation-subtypes"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Registry status on 24 September 2026: terminated, 63 participants (actual), started 6 March 2023 and completed 10 March 2025, United States sites only; no results posted and no publication found in Europe PMC. It was the first KRAS G12D inhibitor in the clinic; the G12D programmes now in phase 3 are zoldonrasib's RASolute 305 and 309."],"nct":"NCT05737706","phase":"1","setting":"A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","sponsor":"Mirati Therapeutics Inc.","started":"2023-03-06","startedType":"actual","enrolled":63,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05737706/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"drug":[{"id":"mrtx1133","kind":"drug","name":"MRTX1133","route":"/drugs/mrtx1133/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"term":[{"id":"kras-mutation-subtypes","kind":"term","name":"KRAS mutation subtypes (G12C, G12D, G12V)","route":"/terms/kras-mutation-subtypes/"},{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/"}]}}